랠리바이오(RLYB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $16.99 (+0.18%), 시가총액 $0.08B, 52주 범위 $0.29 ~ $14.66.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to
랠리바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
랠리바이오의 현재 주가는 $16.99 (+0.18%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
랠리바이오의 시가총액은 약 $0.08B입니다.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its